News & Views

Telix today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the Phase III ARASTEP study (ClinicalTrials.gov Identifier: NCT05794906). This global study is investigating the efficacy of Bayer’s androgen receptor inhibitor (ARi) darolutamide plus androgen deprivation therapy (ADT) versus ADT alone in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence who have no evidence of metastatic disease by conventional imaging and a positive PSMA-PET/CT[2] at baseline.

Telix today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for intravenous injection].

Telix today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118).

Telix will showcase further detailed analyses from the Company’s completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be presented in a late-breaking oral presentation at the American Urological Association (AUA) Annual Meeting being held in Chicago from 28 April to 1 May 2023.

Telix today announces the expansion of its artificial intelligence (AI) capability with the signing of an agreement to acquire Vienna-based Dedicaid GmbH (Dedicaid), a spin-off of the Medical University Vienna.

Telix is pleased to provide notice that the Annual General Meeting of the Shareholders of Telix Pharmaceuticals Limited (ACN 616 620 369) will be convened on Wednesday 24 May 2023.

Telix is pleased to provide a video recording of the joint webcast with Telix’s exclusive partner for the Greater China market, Grand Pharma held on 20 April 2023.

Telix today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 March 2023 (Q1 2023). All figures are in AUD$ unless otherwise stated1 and provided on an unaudited basis.

Telix today announces successful preclinical development of radiolabelled olaratumab, an antibody licensed from Eli Lilly and Company (Lilly). Telix has demonstrated proof-of-concept (PoC) of using olaratumab to selectively deliver both diagnostic and therapeutic radiation to tumours as a radiopharmaceutical moiety and has produced a candidate for clinical translation. Telix will now progress to first-in-human clinical studies based on these highly encouraging results.

Telix today announces the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has approved a Phase I study of TLX101 investigational therapy (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in Chinese patients with newly diagnosed glioblastoma (GBM).